Munzinger Robert, von Brackel Felix N, Bartosik Mikolaj, Barvencik Florian, Amling Michael, Oheim Ralf
Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 22529 Hamburg, Germany.
JBMR Plus. 2025 Mar 18;9(5):ziaf032. doi: 10.1093/jbmrpl/ziaf032. eCollection 2025 May.
Stable calcium isotope fractions have long been related to the calcium metabolism in living organisms. The blood and urine proportions of calcium isotopes Ca and Ca (δCa) have recently again attracted attention as a potential diagnostic tool in metabolic bone diseases, in particular osteoporosis. The hypothesis is that the lighter isotopes (Ca) get incorporated into bone more quickly; hence, δCa ratios in urine and serum are higher for bone formation and lower for resorption phases. Therefore, δCa in blood and urine may serve as an indicator of bone metabolism, potentially reflecting bone density in general. We have conducted clinical characterization by means of laboratory assessment, bone densitometry, HRpQCT, and isotope analysis to test for the hypothesis in patients with monogenic bone diseases. We included 40 adult subjects with hereditary bone diseases, such as early-onset osteoporosis ( = 7), osteogenesis imperfecta ( = 12), hypophosphatasia ( = 12), and X-linked hypophosphatemia (XLH, = 9), and controls ( = 17). Regression analyses revealed significant correlations of δCa with Ca/creatinine ( = 0.6200, < .0001), and bone densitometric parameters were significantly correlated with δCa (BMD: δCa = 0.2685, ≤ .001; δCa = 0.3554; < .0002). XLH differed significantly from the other diseases and controls by means of higher δCa. Our results suggest that δCa is strongly coupled to urinary calcium excretion in patients with hereditary bone diseases. Significant correlations with BMD suggest an interaction of δCa and bone mass though it lacks discriminative power. Further studies are needed to evaluate the utility of δCa in clinical practice.
稳定钙同位素组分长期以来一直与生物体中的钙代谢相关。钙同位素Ca和Ca(δCa)在血液和尿液中的比例最近再次引起关注,成为代谢性骨病,尤其是骨质疏松症的一种潜在诊断工具。其假设是较轻的同位素(Ca)更快地融入骨骼;因此,在尿液和血清中,δCa比值在骨形成时较高,在骨吸收阶段较低。所以,血液和尿液中的δCa可能作为骨代谢的一个指标,有可能总体反映骨密度。我们通过实验室评估、骨密度测定、高分辨率外周定量CT和同位素分析进行了临床特征分析,以检验单基因骨病患者的这一假设。我们纳入了40名患有遗传性骨病的成年受试者,如早发性骨质疏松症(n = 7)、成骨不全症(n = 12)、低磷酸酯酶症(n = 12)和X连锁低磷血症(XLH,n = 9),以及对照组(n = 17)。回归分析显示δCa与Ca/肌酐显著相关(r = 0.6200,P <.0001),并且骨密度测定参数与δCa显著相关(骨密度:δCa r = 0.2685,P≤.001;δCa r = 0.3554,P <.0002)。XLH的δCa值明显高于其他疾病和对照组。我们的结果表明,在遗传性骨病患者中,δCa与尿钙排泄密切相关。与骨密度的显著相关性表明δCa与骨量之间存在相互作用,尽管它缺乏鉴别能力。需要进一步研究来评估δCa在临床实践中的效用。